Introduction
The Philadephia chromosome (Ph) is the hallmark of chronic myeloid leukemia (CML). It is also found in 5% of children and 20-30% of adults with acute lymphoblastic leukemia (ALL). 1 Ph results from the balanced t(9;22) chromosomal translocation, which gives rise to an abnormal fusion protein BCR-ABL. This BCR-ABL protooncogene is detected in two variant forms according to the breakpoint cluster region (bcr): p210 for the major breakpoint cluster region (M-bcr) or p190 for the minor breakpoint cluster region (m-bcr). The p210 protein is usually found in CML patients and in 25-50% of adults with de novo Ph-positive ALL, whereas the p190 protein is found in 90% of childhood Ph-positive ALL. 2, 3 Both p210 and p190 transcripts can be detected by specific BCR-ABL reverse transcriptase polymerase chain reaction (RT-PCR) assays. 4 The prognostic significance of the bcr subtype has not been well established to date. A recent report suggested, however, that the expression of the p190 transcript was associated with a significant increase in the risk of relapse after bone marrow transplantation as compared to the expression of the p210 variant. 5 Ph-positive ALL is a subgroup of ALL with a poor prognosis in both children and adults. [6] [7] [8] After complete remission (CR) achievement, CR duration is short in patients treated with conventional intensive chemotherapy, at least in adults. However, it has recently been reported that the disease can be controlled by chemotherapy alone in a subset of children with a low leukocyte count at diagnosis. 9 To date, allogeneic hematopoietic stem cell transplantation (HSCT) has been considered to be the best treatment option in Ph-positive ALL patients in first CR. 10 In a smaller series, a 2-year relapse-free survival of about 40% is usually observed after allogeneic HSCT either with related or unrelated identical donors. [11] [12] [13] [14] [15] [16] However, relapse remains the main cause of failure with reported posttransplant relapse rates of between 40 and 60%. 9, 11, 12, 15 The detection of residual BCR-ABL fusion transcripts during the post-transplant period may be useful to diagnose recurrent disease early, allowing early therapeutic interventions, such as donor lymphocyte infusions or alpha interferon. 5, 17, 18 The detection of residual BCR-ABL fusion transcripts before transplantation might also provide useful information to stratify patient prognosis.
The aim of the present retrospective study including 121 patients, all prospectively included in French multicenter adult and childhood Ph-positive ALL trials between 1992 and 2000, was to evaluate the results of allogeneic HSCT in these patients in terms of outcome and molecular followup, and to study the prognostic value of pretransplant characteristics, such as BCR-ABL status.
Patients and methods

Patient characteristics
From 1992 to 2000, 150 consecutive allogeneic HSCT for patients with Ph-positive ALL were reported to the registry of the French Society of Bone Marrow Transplantation (SFGM-TC). In order to minimize biases usually associated with registry studies, we chose to analyze only those 121 patients previously enrolled in one of the three main French prospective ALL trials used during this period: FRALLE-93 for children, 19 GOELAL-1/2, 20 and LALA-94 21 for adults. Patient characteristics are summarized in Table 1 . There were 63 males and 58 females who had received HSCT in 27 centers. Two groups were analyzed: 102 adults with a median age of 38 years (range, 18-53) and 19 children with a median age of 8 years (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Median white blood cell count (WBC) was 19 Â 10 9 /l (range, 1-500) for the entire population, 36 Â 10 9 /l (range, 1-382) in children, and 18 Â 10 9 /l (range, 1-500) in adults. All patients had B-lineage ALL. Among the 102 adults, 61 were in first complete remission (CR1) and 41 had advanced disease (six in CR2, one in CR3, and 34 in refractory disease), while 15 children were in CR1, three in CR2, and one had refractory disease. The median time between diagnosis and transplantation was 133 days (range, 78-303) for the 76 patients grafted in CR1 and 132 days (range, 53-580) for the 35 patients grafted with refractory disease. All the 10 patients transplanted in CR2 or CR3 were early relapsing with a median time between diagnosis and transplantation of 224 days (range, 115-1803). In patients transplanted in CR1, the median time to reach CR was 1.4 months (range, 21 days to 4.5 months).
In all, 74 adults and one child were treated on the LALA-94 trial and received the chemotherapy as scheduled. 21 The induction course was administered over a 4-week period and consisted of prednisone, vincristine, cyclophosphamide, and daunorubicin or idarubicin according to initial randomization. At day 35, all patients were eligible for a second course of consolidation (or salvage), whatever the response to induction. This course consisted of mitoxantrone and intermediate-dose cytarabine. Central nervous system prophylaxis consisted of five intrathecal methotrexate, cytarabine, and steroid injections. Transplantation with sibling or identified matched unrelated donor stem cells was planned to be performed in CR1 3 months after In total, 25 adults and one child were treated according to the GOELAL-1/2 trial. 20 The induction course was administered in two phases. The first 4-week phase consisted of prednisone, vincristine, cyclophosphamide, and idarubicin, and was followed by a second phase with cyclophosphamide, cytarabine and 6-mercaptopurine. Transplantation was planned after one or two additional courses of high-dose methotrexate in CR1 patients and after one additional course of cyclophosphamide, cytarabine, and prednisone in patients who had failed this twophase induction. Central nervous system prophylaxis consisted of six intrathecal methotrexate and steroid injections. All patients grafted with advanced disease had failed at least three lines of intensive chemotherapy or were in very early relapse.
In total, 17 children and three young adults were treated according to the pediatric FRALLE-93 trial. 19 The induction course consisted of daunorubicin, vincristine, l-asparaginase, and prednisone administered within a 4-week period. Induction was followed by three cycles of intensive consolidation: (1) two 'R2' cycles with intermediate-dose cytarabine, etoposide, and dexamethasone; and (2) one 'COPADEM' cycle with vincristine, high-dose methotrexate, cyclophosphamide, adriamycin, and prednisone. Children received six intrathecal methotrexate, cytarabine, and steroid injections. Transplantation was planned after the third cycle of intensive consolidation in children in CR1. One patient who had failed three induction courses was transplanted with refractory disease.
Diagnostic criteria for Ph-positive ALL
The diagnosis of Ph-positive ALL was based on standard cytogenetic and/or on RT-PCR at diagnosis. Chromosome analysis was performed using short unstimulated cultures on bone marrow and/or peripheral blood samples. A minimum of 20 mitoses were fully analyzed, standard criteria to define a clone were applied, and chromosomal abnormalities were classified according to the International System for Human Cytogenetic Nomenclature. 22 RT-PCR specific for BCR-ABL rearrangements was performed on bone marrow and/or peripheral blood samples. The RT-PCR reaction was carried out following a common protocol using already published BCR-ABL primers, 2, 23 as described. 24 More recently, the standardized BIOMED-1 primers were used. 25 Patients for whom the samples had no amplification of control gene expression were excluded from the molecular part of analysis but remained in the clinical analysis. Sensitivity of the reaction was assessed during each experiment using a dilution series of Tom1 (m-BCR) or K562 (M-BCR) RNA. It ranged from 10 À4 to 10 À5 with a median of 10
À5
. Immunophenotyping of ALL cells was systematically performed on bone marrow and/or peripheral samples using usual monoclonal antibodies. As scheduled in the three chemotherapy trials, all cytogenetic, molecular, and immunophenotyping data were prospectively and centrally reviewed by three distinct working committees. At diagnosis, 46 patients (two children and 44 adults) had M-bcr ALL, 31 (12 children and 19 adults) had m-bcr ALL, and two adults had mM-bcr ALL. The bcr subtype was missing in 41 patients and testing was negative in only one case.
Choice of donor
An indication of allogeneic HSCT was scheduled in the three chemotherapy trials whenever a diagnosis of Phpositive and/or BCR-ABL-positive ALL was made. If a geno-identical donor was not available, a search for an unrelated donor on National and International bone marrow donors registries was initiated. The unrelated allograft was performed as soon as an HLA identical donor was identified. The selection criterion was HLA typing and this varied with time: between 1992 and 1994 identity of A and B class I antigens were defined by serology and class II antigens were defined using restriction fragment length polymorphism. No disparity was allowed in choosing the donor. After 1994, selection criteria were defined by the identity for class I antigens using PCRsequence-specific probes (PCR-SSP) and for class II antigens using restriction fragment length polymorphism. Since this time, only one disparity out of 10 antigens tested (HLA-A, -B, -C, -DR, -DQ) was allowed in selecting the potential donor. The time of such a search did not exceed 3 months after CR and patients without a suitable donor after this time received alternative treatment of chemotherapy alone or a scheduled autologous transplant. The median time between CR1 and transplantation was 2.6 months (range, 0.7-5.5 months) for the whole population, 2.3 months (range, 0.7-5 months) for the transplants with a sibling donor, and 3.7 months (range, 1.2-5.5 months) for the grafts with an unrelated donor.
Minimal residual disease analysis before transplantation
Pretransplant RT-PCR was performed in 85/121 (70%) patients, including 52 CR1 and six CR2 in whom RT-PCR analysis was performed on bone marrow samples. In all, 35 of the 52 CR1 patients had persistent BCR-ABL transcripts, while 17 had no detectable minimal residual disease. Two of the six CR2 patients had no detectable transcripts at the time of transplantation.
Transplantation modalities
The conditioning regimen varied between adults and children. The majority of children (12 out of 19) received a 'TAMe', including fractionated total body irradiation (FTBI) (12 grays in six fractions), cytarabine 12 or 18 g/m 2 , and melphalan 140 mg/m 2 as previously described. 26 Two children under 4 years of age received conditioning without FTBI. In total, 48 adults received 12 grays in six fractions FTBI with cyclophosphamide (CY) 120 mg/kg given over 2 days and etoposide at 50 mg/kg in one dose. Nine young adults received 'TAMe' conditioning, and four received conditioning without FTBI (of whom two had a nonmyeloablative conditioning regimen). Other adults received a combination of the same dose of FTBI and CY with or without thiotepa at 10 mg/kg in one dose.
In all, 11 children received HSCT from a sibling (eight bone marrow cells, two cord blood cells, and one peripheral blood stem cell), two received family mismatched bone marrow and peripheral blood stem cells, and six received an unrelated graft (five bone marrow cells and one cord blood cells). In all, 76 adults received HSC from a sibling (62 with marrow cells and 14 peripheral blood stem cells), and 26 from an unrelated donor (with one cord blood cells). The median number of nucleated cells transfused was 2.8 Â 10 8 / kg (range, 0.1-15.3).
Only two children and six adults were given a T-celldepleted HSC and the other patients received the usual graft-versus-host disease (GvHD) prophylaxis with cyclosporin A given from day À1 for at least 6 months posttransplant and three or four doses of methotrexate 15 mg/ m 2 on day 1 and 10 mg/m 2 on days 3, 6711. Engraftment was defined as the first of three consecutive days when the absolute neutrophil count (ANC) exceeded 0.5 Â 10 9 /l. Granulocyte colony-stimulating factor (G-CSF) was given only in cases of delayed engraftment. Acute GvHD was graded using Gluckberg's criteria, 27 with modifications introduced in 1996. 28 Patients were considered at risk for chronic GvHD if they were alive with engraftment beyond day 100 post-transplant and were classified as having limited or extensive chronic GvHD. 29 For comparison, patients with grade 2 or higher acute GvHD were compared to those with ograde 2 or no acute GvHD, while patients with limited or extensive chronic GvHD were compared to those without chronic GvHD. All patients were transplanted in high-efficiency particle air filtration rooms. CMV-negative pretransplant patients received CMV seronegative blood products. All patients with CMV reactivation had received pre-emptive ganciclovir treatment. Empiric and curative antibacterial and antifungal treatment differed from one center to another but was based on an intravenous combination of thirdgeneration beta-lactamines with aminoside and/or glycopeptide and amphotericin B. Cotrimaxazole was given to prevent Pneumocystis pneumonia for the first 6 months, and then lifelong penicillin was started. Chimerism studies consisted of in situ hybridization of the Y chromosome among patients whose donor was of the opposite sex, or molecular study of the variable number of tandem repeat polymorphism.
Minimal residual disease analysis after transplantation
No antileukemia treatment was given systematically after transplantation. Minimal residual disease analysis was not uniformly scheduled and left to the discretion of each center. Bone marrow and/or peripheral blood samples from 94 patients were submitted to RT-PCR analysis at various points before the graft and between 1 month and five and a half years after transplantation, with a mean of three points per patient. Nine patients tested during follow-up were not tested before transplantation. Therapeutic approach with regard to molecular follow-up was not scheduled. In the same way, treatment of relapse including chemotherapy (combination of vincristine, prednisolone, and various other drugs), Interferon-a and donor lymphocyte infusion (DLI) was given according to different protocols without standardized recommendation.
Statistical analysis
Follow-up has been updated as of 31 December, 2000. The Fisher exact test was used for binary variable comparison. Duration of CR was calculated from the date of the graft until the date of first hematological relapse. Data on treatment failure were estimated by the Kaplan-Meier method 30 and compared using the log-rank test. 31 In multivariate analyses, outcome comparisons were adjusted with the Cox model 32 and tested by the likelihood-ratio test. In univariate as well as in multivariate analysis, acute and chronic GvHD significance were considered as time-dependent variables and their impacts on outcome were evaluated using multiple-record survival data. A P-value of less than 0.05 was considered as reaching statistical significance. All calculations were performed using the STATA software, version 7.0 (Stata Corporation, TX, USA).
RESULTS
Overall survival
The median follow-up for the 43 living patients was 29 months (range, 1-107 months). At 2 years, the estimated overall survival was 37% (95% confidence interval, 28-46%). Prognostic factors for survival are shown in Table 2 . Patients receiving HSCT in CR1 had a 2-year survival of 50% (95% confidence interval, 37-61%) as compared to 17% (95% confidence interval, 8-29%) in patients grafted with more advanced disease (Po0.0001) (Figure 2a ). (Figure 3a ). Children had a 2-year survival of 58% (95% confidence interval, 33-76%) as compared to 33% (95% confidence interval, 23-42%) in adults (P ¼ 0.04) (Figure 4a ). This was associated with a longer survival in patients enrolled in the pediatric FRALLE-93 study as compared to adults enrolled in both LALA-94 and GOELAL-1/2 studies (P ¼ 0.05). Type of donor (sibling or unrelated donor) and type of transcript (M-bcr or m-bcr) had no significant influence on survival. The occurrence of acute GvHD (grade 2 or more) or chronic GvHD did not significantly influence survival (P ¼ 0.60 and 0.85, respectively, when both variables were considered as time-dependent variables). On multivariable analysis (including hematological status at the time of HSCT, age considered as a continuous variable, WBC considered as a continuous variable, and chemotherapy trial), the only independent factor associated with longer survival was hematological status (relative risk in patients grafted in conditions other than CR1, 2.6; 95% confidence interval, 1.6-4.2; Po0.0001) ( Table 2) .
Of note, the estimated 4-year survival for patients who received an allograft in CR1 was 42% (95% confidence interval, 29-54%) vs 5% (95% confidence interval, 0-18%) for patients with more advanced disease. Only one patient from the latter group became a long-term survivor.
Post-transplant morbidity and mortality
Children: All children had myeloid reconstitution except one who received an autologous rescue graft after failure of a mismatched unrelated graft. The median time to recover 0.5 Â 10 9 /l ANC was 21 days (range, 14-43). Chimerism studies performed in the first 3 months after HSCT showed full engraftment of donor cells in all the eight patients tested. In all, 10 children experienced grade X2 acute GvHD (six after sibling HSCT, three after unrelated HSCT, and one after related mismatched graft). Of 13 children alive at 3 months, four had limited chronic GvHD and one extensive chronic GvHD. Six of 19 children (32%) relapsed at a median of 3.5 months (range, 2-40). Eight children died: five from relapse, one from acute GvHD, one from viral, and one from fungal infection.
Adults: Of 102 patients, 90 had myeloid reconstitution with a median time to an ANC of 0.5 Â 10 9 /l of 20 days (range, 9-59). A total of 11 patients had no hematological recovery and died from infection or grade IV GvHD within Allogeneic HSCT in Ph-positve ALL H Espérou et al the first month after HSCT. One patient without engraftment after T-cell-depleted HSCT had myeloid recovery after a second unmanipulated allograft. In total, 53 (52%) patients experienced grade X2 acute GvHD (40 after sibling HSCT and 13 after unrelated HSCT). Of the 76 patients alive at 3 months, 33 (43%) had chronic GvHD (20 patients with limited form and 13 patients with extensive form). In all, 35 adults (34%) relapsed within a median of 7 months (range, 1-43). In total, 70 patients died: 27 from relapse, 21 from toxicity, 18 from infection, and four from GvHD.
Minimal residual disease follow-up
Minimal residual disease was serially assessed before and/ or after HSCT in 96 patients, at one to five time points per patient. Of note, among these, 63 patients had molecular follow-up before and after HSCT (38 in CR1 and 25 with more advanced disease) (Figure 1) . The results may be summarized as follows. First, molecular status before HSCT was unknown in nine patients in CR1. Six of these patients were continuously BCR-ABL negative after HSCT without hematological relapse. Three patients were continuously BCR-ABL positive after HSCT and relapsed.
Secondly, 19 patients (17 in CR1 and two in CR2) were BCR-ABL negative at the time of HSCT. Among the 14 patients with no hematological relapse (74%), eight remained BCR-ABL negative for up to 4 years and six had no molecular follow-up (five of them died in the first 3 months after HSCT). Five patients (26%) experienced a relapse, all after transient negativity of RT-PCR, and BCR-ABL transcript reappearance at 3, 8, 17, 20 , and 43 months. Three patients were treated with chemotherapy without interferon-a, but with DLI in two cases. The two others died before any treatment.
Thirdly, 68 patients were BCR-ABL positive at the time of HSCT. In all, 36 were in CR1, 32 with more advanced disease. Among the 27 patients in CR1 without hematological relapse (75% of CR1 patients), 19 were then BCR-ABL negative (including two who became BCR-ABL negative late, at 2 and 6 months postHSCT) and eight had no molecular follow-up (four of them died early). Among the nine patients who experienced a hematological relapse, one was continuously BCR-ABL positive after HSCT, seven were transiently RT-PCR negative before the diagnosis of relapse (at 3, 4, 7, 10, 11, 12, and 28 months, respectively), and the remaining one had no molecular follow-up. Six patients were treated with chemotherapy without interferon-a, but with DLI in four cases. Among the 19 patients with more advanced disease and without hematological relapse (60% of non-CR1 patients), 11 Allogeneic HSCT in Ph-positve ALL H Espérou et al remained BCR-ABL negative (one became BCR-ABL negative late, at 2 months), six had no molecular followup until transplant-related death, and two died from infection with a positive BCR-ABL transcript. Among the 13 patients with more advanced disease who experienced a relapse, five were continuously BCR-ABL positive, four were transiently RT-PCR negative before the diagnosis of relapse (at 3, 9, 14, and 16 months, respectively), and four had no molecular follow-up (three of them died early). Four patients died before any treatment. Nine patients received chemotherapy with DLI in three cases; all of them died from relapse. In five patients (including three BCR-ABL positive patients at the time of HSCT), BCR-ABL negativity was observed at 1, 3, 5, 7, and 10 months only after a post-HSCT BCR-ABL-positive period. In all other patients, BCR-ABL positivity was predictive of relapse.
Hematological relapse
At 2 years, the probability of relapse was 44% (95% confidence interval, 34-56%). Prognostic factors associated with relapse are shown in Table 3 . The 2-year estimated relapse rate was 37% (95% confidence interval 25-51%) in patients who received HSCT in CR1 as compared to 62% (95% confidence interval, 41-83%) in those with more advanced disease (P ¼ 0.01) (Figure 2b ). For patients in CR1 the 2 years estimated relapse rate was similar whatever the molecular status at the time of HSCT (Figure 3b) . The 2-year estimated relapse rate was similar in children and adults (Figure 4b) . On univariate analysis, the occurrence of acute GvHD was associated with a lower risk of relapse. At 2 years, the risk of relapse was 38% (95% confidence interval, 24-56%) in patients with grade II or higher acute GvHD vs 53% (95% confidence interval, 39-69%) in patients with ograde II acute GvHD (P ¼ 0.06, when acute GvHD was considered as a time-dependent variable). Conversely, the occurrence of chronic GvHD had no influence on risk of relapse but the shortness of median follow-up does not allow assessment of the role of chronic GvHD, which may not yet have manifested.
A three-variable analysis, including hematological status at the time of HSCT, WBC considered as a binary variable (more or less than 25 Â 10 9 /l), and acute GvHD considered as a time-dependent variable, was performed. The following two factors were identified as significantly associated with a lower risk of relapse: (1) CRl status (relative risk for patients grafted in conditions other than CR1, 2.4; 95% confidence interval, 1.2-4.7; P ¼ 0.02); (2) a grade XII acute GvHD (relative risk for patients without acute GvHD, 2.3; 95% confidence interval, 1.2-4.5; P ¼ 0.02) ( Table 3) .
In patients tested for BCR-ABL status between 3 and 6 months after HSCT, we found, however, an correlation between the occurrence of acute GvHD and molecular status at that time. Among the 51 BCR-ABL-negative patients, 29 had experienced grade X2 acute GvHD; among the 13 BCR-ABL-positive patients, seven had experienced acute GvHD (P ¼ 1.0, by the w 2 test). Among the five patients with delayed development of BCR-ABL negativity, two had experienced a grade X2 acute GvHD and three had not. Of note, there were more patients alive after 3 months and without BCR-ABL status assessment after HSCT who experienced acute GvHD 19/57 than patients with BCR-ABL status assessment after HSCT who experienced acute GvHD 13/43.
Donor lymphocyte infusion
Nine patients received one or more donor lymphocyte infusions (Table 4) . For one patient with molecular relapse at 3 years after HSCT this was the only treatment, and two infusions of 1 Â 10 7 CD3+ cells/kg led to a prolonged complete molecular remission. The other patients received DLI associated with chemotherapy and always for hematological relapse at a median of 10 months. Five patients achieved a response; for two this was a prolonged complete molecular remission (more than 9 and 12 months), but three died from relapse or fungal infection after only a transient response. Three patients had no response.
Discussion
Allogeneic HSCT is considered to be the best treatment option for patients with Ph-positive ALL in first CR. This has been recently confirmed in a French prospective study comparing this approach with autologous HSCT in 103 Table 2 footnote.
Allogeneic HSCT in Ph-positve ALL H Espérou et al CR1 patients using the intention-to-treat principle. 21 The reported estimated 2-year survival of 50% in 76 patients who received allogeneic HSCT in first CR is similar to the reports after allogeneic transplantation in smaller unicenter populations of patients with the same disease, as recently reviewed by Snyder. 10 Survival rates observed in patients treated with chemotherapy alone are usually much lower. 14, [33] [34] [35] In a recent worldwide pediatric retrospective study performed on 267 children stratified into three prognostic subgroups according to age and white cell count, a significant survival advantage was observed in children who received sibling HSCT (N ¼ 38) as compared to those treated with chemotherapy alone (N ¼ 147) within each prognostic subgroup. 9 From using retrospective data including variable patient populations (children and adults, patients with different hematological and molecular situations, geno-or phenoidentical donors) we can draw some conclusions.
First, hematological status at the time of HSCT (CR1) appears to be a favorable prognostic factor for overall survival and for leukemia-free survival. Transplantation can thus be recommended at that time: achievement of a second remission after relapse is rare 33 and a worse outcome after HSCT for patients in second CR or with more advanced ALL has recently, been emphasized by the study of Snyder et al. 36 In the present study, only one of the 45 patients who received HSCT for advanced ALL was alive at 4 years. Furthermore, the lack of difference in terms of survival between sibling and unrelated donor transplantation observed in our study leads to the recommendation of a search for a matched unrelated donor in CR1 patients with no sibling donor. Recently, Cornelissen et al 37 reported a 37713% DFS for patients with poor-risk ALL (who were mainly Ph-positive) who received unrelated marrow transplantation in CR1. 37 It may be assumed from this study that there is a stronger graft-versus-leukemia (GvL) effect after unrelated marrow transplantation, which offsets the potential higher transplant-related mortality risk. This enhanced GvL effect in Ph-positive ALL can be paralleled to the best known GvL effect after allogeneic transplantation in CML initially reported by Sierra et al. 16 It can also be linked to the comparative efficacy of DLI in these patients with regard to the usual lack of DLI efficacy in ALL.
Secondly, with classical BCR-ABL RT-PCR, the postallograft monitoring of minimal residual disease gave quite interesting results. Analysis of molecular follow-up profiles shows a good correlation between RT-PCR positivity and relapse. A similar correlation was reported in several studies, 5, 7, 18 while not observed in the studies from Snyder 10 and Sierra et al, 16 who both reported patients with persistent BCR-ABL transcripts until 2 years after their graft who did not relapse. In our study, all patients with reappearance of the BCR-ABL transcript after initial postgraft negativity relapsed and the only patients who remained alive after relapse were those who received early DLI. Since efficiency is also an argument in favor of a significant GvL effect of allogeneic transplantation in this situation. We report a small proportion of patients who were BCR-ABL positive the first months of follow-up and who became spontaneously negative a few weeks later. This is also reported by Marks et al 15 in a pediatric study. Despite the prognostic influence of acute GvHD on relapse on multivariate analysis and the high predictive value of post-HSCT BCR-ABL status on hematological relapse, we observed no difference in GvHD incidence between patients with and without positive minimal residual disease. This lack of correlation may be related to the introduction of two biases. First, some patients had hematological relapse before post-HSCT BCR-ABL status assessment. Secondly, not all eligible patients (ie patients alive after 3 months) were tested for post-HSCT BCR-ABL status. The subtype of BCR-ABL transcript does not, in our study relate to risk of relapse as reported by Radich et al 5 and Snyder et al, 38 but not by others inducing Kro¨ger et al.
39
All these issues emphasize the place of allogeneic HSCT in the treatment of Philadelphia-positive ALL. The lack of prognostic significance of the molecular BCR-ABL status just before the graft has to be confirmed or refuted by further evaluations eventually using quantitative real-time PCR in a larger number of patients. It may be an argument in favor of a GvL effect after DLIs in patients with molecular relapse or it may demonstrate the importance of GvHD as a factor protecting against relapse. The large proportion of patients who relapse after allogeneic transplantation suggests, however, that further evaluations should be undertaken using new antileukemia agents such as Gleevect either in the pretransplant or posttransplant periods.
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